Sector News

Deal-weighing Pharmacyclics could draw $18B from J&J, Novartis: Bloomberg

February 26, 2015
Life sciences
So far, the 2014 pharma deal blitz has continued right on into 2015. And cancer drugmaker Pharmacyclics could be the next company to keep it going.
 
The California company, which boasts a market value of almost $15 billion, is exploring its options–and those include a sale, Bloomberg’s sources say. While deliberations are still in the early stages, Pharmacyclics already reportedly has some big-name suitors circling, including Johnson & Johnson and Novartis.
 
While a potential deal for the Sunnyvale-based company–which could draw bids as high as $17 billion or $18 billion, Bloomberg notes–would be the biggest in the industry so far this year, it’s nothing the pharma giants couldn’t swallow. And drugmakers may be eager to get their hands on Imbruvica, the blood cancer drug that last month scored its fourth FDA approval.
 
For J&J, the fit would be natural. Its Janssen subsidiary already markets the med outside the U.S. and shares marketing duties with Pharmacyclics at home, and the pair is working together to try to expand Imbruvica’s patient pool. But J&J isn’t the company’s only partner; it’s also teamed up with drugmakers the likes of Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene and Roche  to study Imbruvica as part of cancer-fighting combos.
 
And for Novartis, which already boasts a pair of blood-cancer powerhouse treatments in Gleevec and Tasigna, the pickup makes sense, too. The Basel-based pharma giant has been active in the M&A arena as it rides pharma’s slim-down wave, shedding non-core assets and working to strengthen its focus areas. Cancer is high on its priority list, and to that end, it last year agreed to fork over $16 billion in exchange for GlaxoSmithKline’s oncology business–a deal GSK is set to close next week.
 
By Carly Helfand
 

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.